Keenova Therapeutics — Third Quarter 2026 Earnings Summary

Keenova Therapeutics reported third-quarter 2026 net sales of $550 million, driven by a 25% increase in Acthar Gel sales to $227 million and an 82% surge in XIAFLEX sales to $164 million. The company recorded a loss from continuing operations of $96 million but achieved an adjusted EBITDA of $233 million, reflecting strong operational performance and the realization of merger synergies. Keenova raised its full-year 2026 net sales guidance to a range of $2.00 billion to $2.025 billion and adjusted EBITDA guidance to $750 million to $770 million based on improved growth expectations for its core brands. Additionally, the company advanced its XIAFLEX pipeline with an expected sBLA submission for plantar fibromatosis in the first quarter of 2027 and the initiation of a Phase 3 study for hammer toe.